Yazar "Ulas, Turgay" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe ASSESSMENT OF CHARACTERISTICS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ACQUIRED APLASTIC ANAEMIA IN TURKIYE (PLANE-TR STUDY)(Springernature, 2025) Gunduz, Eren; Ulas, Turgay; Ozkalemkas, Fahir; Toprak, Selami Kocak; Karakulak, Elifcan Aladag; Ar, Muhlis Cem; Gulbas, Zafer[No abstract available]Öğe Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR)(Springer, 2026) Gunduz, Eren; Ulas, Turgay; Ozkalemkas, Fahir; Toprak, Selami Kocak; Karakulak, Elifcan Aladag; Ar, Muhlis Cem; Gulbas, ZaferAcquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis to first treatment was 119 +/- 287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212 +/- 321 days, and to Anti-Thymocyte Globulin (ATG) was 87 +/- 242.5 days. The mean time to response after first-line and second-line treatment was 172.9 +/- 264.6 days and 191.9 +/- 211.9 days, respectively. The mean overall survival of patients with AA was 3.56 +/- 3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to previous studies, providing vital insights into Turkiye's acquired AA treatment landscape.Öğe Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption(Pergamon-Elsevier Science Ltd, 2020) Yigenoglu, Tugce Nur; Ulas, Turgay; Dal, Mehmet Sinan; Korkmaz, Serdal; Erkurt, Mehmet Ali; Altuntas, FevziThe activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19.Öğe International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report(Pergamon-Elsevier Science Ltd, 2023) Ozatli, Duzgun; Giden, Asli Odabasi; Erkurt, Mehmet Ali; Korkmaz, Serdal; Basci, Semih; Ulas, Turgay; Turgut, BurhanTherapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful sub-stances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers per-forming therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.Öğe Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients(Pergamon-Elsevier Science Ltd, 2021) Yigenoglu, Tugce Nur; Basci, Semih; Sahin, Derya; Ulas, Turgay; Dal, Mehmet Sinan; Korkmaz, Serdal; Hacibekiroglu, TubaSARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.Öğe What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?(Pergamon-Elsevier Science Ltd, 2025) Ulas, Turgay; Namdaroglu, Sinem; Hindilerden, Ipek Yonal; Erkurt, Mehmet Ali; Erer, Kerim; Yigenoglu, Tugce Nur; Tiryaki, Tarik OnurObjectives: In this study, we aimed to compare the engraftment days, graft versus host disease (GVHD) development, relapse and overall survival (OS) rates in patients using variable intensity conditioning regimens with two different post-transplant cyclophosphamide (PTCy) doses for hematological malignancies. Material and methods: We retrospectively analyzed 162 patients who have had PTCy at a dose of 25 mg/kg x 2 and 50 mg/kg x 2 between 2018 and 2024. Patients were divided in 2 groups; PTCy dose with 25 mg/kg x 2 (Group 1, n = 45) and PTCy dose with 50 mg/kg x 2 (Group 2, n = 117). The engraftment days, GVHD, relapse and OS rates were compared across groups. Results: All patients had myeloablative conditioning regimens and peripheral stem cell collected transplantation. 61.1 % of patients (n = 99) were alive at the end of the study (60 % (n = 27) in Group1 and 61.5 % (n = 72) in Group 2). In Group 1 the median follow-up was 6.9 months and in Group 2 this was 7 months; the median OS was 15.5 months in Group 1 and 49.5 months in Group 2 but this is not statistically significant (Log rank = 0.796). In Group 1, the engraftment times for platelets was 13 days, for neutrophils 17 days; in Group 2, for platelet this was 18 days; and for neutrophils 17 days; this was statistically significant for platelets but not for neutrophil engraftment (p: < 0.001 and p:0.839, respectively). Eighteen patients (40 %) in Group 1 and twenty-seven (23 %) patients in group 2 had acute GVHD (aGVHD). In Group 1 aGVHD rates were higher than Group 2 (p = 0.031). Seven patients (15.5 %) in Group 1 and 6 (5.12 %) patients in group 2 had chronic GVHD (cGVHD). In Group 1 cGVHD rates were also higher than Group 2 (p = 0.048). Twenty-five patients (55.6 %) in Group 1 and 19 patients (16.2 %) in Group 2 had relapsed disease (p < 0.001). Conclusion: Our study showed that there were no differences in survival across the groups. The platelet engraftment time was shorter for the PTCy 25 mg/kg x 2 doses compared to the post-transplantation 50 mg/kg x 2 doses. Both aGVHD and cGVHD rates were higher in 25 mg/kg x 2 dose treated patients. Relapses occurred more commonly with 25 mg/kg x 2 PTCy dose.
